Search - tctmd.com

Displaying 81 - 100 of 208

Sort: Relevancy | Date

News Daily News

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

Michael O'Riordan

April 21, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

Mom’s CV Health in Pregnancy Foretells Child’s Risk Years Later

L.A. McKeown

February 17, 2021

News Daily News

Plaque Burden, Not Coronary Stenosis, Linked to Future Events in Stable CAD

Michael O'Riordan

December 07, 2020

News Conference News AHA 2020

OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients

Todd Neale

November 15, 2020

News Conference News TCT 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

Todd Neale

October 21, 2020

News Conference News EAS 2020

Just One-Third of European Patients Get to LDL Cholesterol Goals

Michael O'Riordan

October 13, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Conference News EAS 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Michael O'Riordan

October 07, 2020

News Daily News

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Michael O'Riordan

September 22, 2020

News Conference News ESC 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Yael L. Maxwell

September 02, 2020

News Daily News

Young Patients With Premature ASCVD Less Likely to Receive Statins, Aspirin

Michael O'Riordan

August 25, 2020

News Daily News

AHA: Increased Diabetes, CVD Risk for American Indians, Alaskan Natives

Yael L. Maxwell

May 29, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Todd Neale

November 18, 2019

News Conference News AHA 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

Shelley Wood

November 18, 2019

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

Advertisement

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Mom’s CV Health in Pregnancy Foretells Child’s Risk Years Later

Plaque Burden, Not Coronary Stenosis, Linked to Future Events in Stable CAD

OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

Just One-Third of European Patients Get to LDL Cholesterol Goals

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Young Patients With Premature ASCVD Less Likely to Receive Statins, Aspirin

AHA: Increased Diabetes, CVD Risk for American Indians, Alaskan Natives

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

FDA Approves Icosapent Ethyl for Reducing CVD Events

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content